BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34:194-203. [PMID: 24337625 DOI: 10.1007/s10875-013-9976-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681-700. [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173] [Cited by in Crossref: 252] [Cited by in F6Publishing: 262] [Article Influence: 36.0] [Reference Citation Analysis]
2 Ou Q, Yu Y, Li A, Chen J, Yu T, Xu X, Xie X, Chen Y, Lin D, Zeng Q, Zhang Y, Tang X, Yao H, Luo B. Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma. Ann Transl Med 2020;8:230. [PMID: 32309377 DOI: 10.21037/atm.2020.01.32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zheng Y, Dou Y, Duan L, Cong C, Gao A, Lai Q, Sun Y. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol. 2015;294:54-59. [PMID: 25687508 DOI: 10.1016/j.cellimm.2015.02.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 7.1] [Reference Citation Analysis]
4 Nakamoto Y. Promising new strategies for hepatocellular carcinoma. Hepatol Res. 2017;47:251-265. [PMID: 27558453 DOI: 10.1111/hepr.12795] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
5 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016; 7(3): 242-255 [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
6 Yu R, Yang B, Chi X, Cai L, Liu C, Yang L, Wang X, He P, Lu X. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis. Drug Des Devel Ther. 2017;11:851-864. [PMID: 28360510 DOI: 10.2147/dddt.s124399] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
7 Ding X, Cao H, Chen X, Zhao Y, Jin H, Niu C, Ma K, Liu Z, Chen J, Wang X, Yang L, He H, Han W, Li D, Tian H, Li W, Cui J. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage. Journal of Cellular Immunotherapy 2016;2:36-43. [DOI: 10.1016/j.jocit.2016.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol 2019;12:52. [PMID: 31142330 DOI: 10.1186/s13045-019-0742-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
9 Qian L, Wang N, Tian H, Jin H, Zhao H, Niu C, He H, Ge T, Han W, Hu J, Li D, Han F, Xu J, Ding X, Chen J, Li W, Cui J. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res. 2016;2016:6837241. [PMID: 27069936 DOI: 10.1155/2016/6837241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
10 Mylonaki I, Allain E, Strano F, Allémann E, Corpataux JM, Meda P, Jordan O, Delie F, Rougemont AL, Haefliger JA, Saucy F. Evaluating intimal hyperplasia under clinical conditions. Interact Cardiovasc Thorac Surg 2018;27:427-36. [PMID: 29617792 DOI: 10.1093/icvts/ivy101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
11 Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12:707-714. [PMID: 27347204 DOI: 10.3892/ol.2016.4629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
12 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
13 Gu Y, Lv H, Zhao J, Li Q, Mu G, Li J, Wuyang J, Lou G, Wang R, Zhang Y, Huang X. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC). Int Immunopharmacol 2017;50:263-9. [PMID: 28711032 DOI: 10.1016/j.intimp.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
14 Ji Z, Meng G, Huang D, Yue X, Wang B. NMFBFS: A NMF-Based Feature Selection Method in Identifying Pivotal Clinical Symptoms of Hepatocellular Carcinoma. Comput Math Methods Med 2015;2015:846942. [PMID: 26579207 DOI: 10.1155/2015/846942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
15 Floudas CS, Brar G, Greten TF. Immunotherapy: Current Status and Future Perspectives. Dig Dis Sci 2019;64:1030-40. [DOI: 10.1007/s10620-019-05516-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
16 Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2019;68:23-32. [PMID: 30232520 DOI: 10.1007/s00262-018-2247-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
17 Ren PT, Zhang Y. Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells. Mol Med Rep 2017;15:1533-8. [PMID: 28260039 DOI: 10.3892/mmr.2017.6175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021;15:155-69. [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3] [Reference Citation Analysis]
19 Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086. [PMID: 30377451 DOI: 10.1177/1756284818808086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Brown ZJ, Greten TF. Immune Therapies. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 239-53. [DOI: 10.1007/978-3-030-21540-8_12] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Shokoohian B, Negahdari B, Aboulkheyr Es H, Abedi-Valugerdi M, Baghaei K, Agarwal T, Maiti TK, Hassan M, Najimi M, Vosough M. Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. J Cell Mol Med 2021;25:8602-14. [PMID: 34423899 DOI: 10.1111/jcmm.16875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Cai XR, Li X, Lin JX, Wang TT, Dong M, Chen ZH, Jia CC, Hong YF, Lin Q, Wu XY. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review. Oncotarget 2017;8:31318-28. [PMID: 28412743 DOI: 10.18632/oncotarget.15454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
23 Mata-Molanes JJ, Sureda González M, Valenzuela Jiménez B, Martínez Navarro EM, Brugarolas Masllorens A. Cancer Immunotherapy with Cytokine-Induced Killer Cells. Target Oncol 2017;12:289-99. [PMID: 28474278 DOI: 10.1007/s11523-017-0489-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
24 Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112-127. [PMID: 33235387 DOI: 10.1038/s41423-020-00572-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
25 Aravalli RN, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes (Basel) 2017;8:E76. [PMID: 28218682 DOI: 10.3390/genes8020076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
26 Bonilla CM, McGrath NA, Fu J, Xie C. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Res. 2020;6. [PMID: 33134550 DOI: 10.20517/2394-5079.2020.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Mo HY, Liao YY, You XM, Cucchetti A, Yuan BH, Li RH, Zhong JH, Li LQ. Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy. PLoS One 2017;12:e0174222. [PMID: 28339493 DOI: 10.1371/journal.pone.0174222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
28 Giraudo L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. Immunotherapy 2015;7:999-1010. [PMID: 26310715 DOI: 10.2217/imt.15.61] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
29 Mandriani B, Pelle' E, Pezzicoli G, Strosberg J, Abate-Daga D, Guarini A, Cives M, Porta C. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treat Rev 2021;100:102288. [PMID: 34525422 DOI: 10.1016/j.ctrv.2021.102288] [Reference Citation Analysis]
30 Wang J, Shen T, Wang Q, Zhang T, Li L, Wang Y, Fang Y. The long-term efficacy of cytokine-induced killer cellular therapy for hepatocellular carcinoma: a meta-analysis. Immunotherapy 2019;11:1325-35. [PMID: 31578914 DOI: 10.2217/imt-2019-0079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Baradaran Noveiry B, Hirbod-Mobarakeh A, Khalili N, Hourshad N, Greten TF, Abou-Alfa GK, Rezaei N. Specific immunotherapy in hepatocellular cancer: A systematic review. J Gastroenterol Hepatol 2017;32:339-51. [PMID: 27206802 DOI: 10.1111/jgh.13449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
32 Li W, Xu L, Wang Y, Zhao L, Kellner DB, Gao Q. Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma. J Immunol Res 2017;2017:1092507. [PMID: 28913367 DOI: 10.1155/2017/1092507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Rui T, Cheng X, Wu H, Wang F, Ye Z, Wu G. Lentiviral delivery of CTLA-4 shRNA improves the expansion of cytokine-induced killer cells and enhances cytotoxic activity in vitro. Oncol Lett 2018;15:741-6. [PMID: 29399145 DOI: 10.3892/ol.2017.7376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Ding X, Cao H, Chen X, Jin H, Liu Z, Wang G, Cai L, Li D, Niu C, Tian H, Yang L, Zhao Y, Li W, Cui J. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med 2015;13:158. [PMID: 25968637 DOI: 10.1186/s12967-015-0514-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
35 Nakano S, Eso Y, Okada H, Takai A, Takahashi K, Seno H. Recent Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E775. [PMID: 32218257 DOI: 10.3390/cancers12040775] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
36 Zhang L, Ding J, Li HY, Wang ZH, Wu J. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim Biophys Acta Rev Cancer 2020;1874:188441. [PMID: 33007432 DOI: 10.1016/j.bbcan.2020.188441] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
37 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Zhang R, Zhang Z, Liu Z, Wei D, Wu X, Bian H, Chen Z. Adoptive cell transfer therapy for hepatocellular carcinoma. Front Med 2019;13:3-11. [DOI: 10.1007/s11684-019-0684-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
39 Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer 2017;87:101-12. [PMID: 29145036 DOI: 10.1016/j.ejca.2017.10.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
40 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Sullivan KM, Kenerson HL, Pillarisetty VG, Riehle KJ, Yeung RS. Precision oncology in liver cancer. Ann Transl Med 2018;6:285. [PMID: 30105235 DOI: 10.21037/atm.2018.06.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
42 Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2015;141:839-49. [PMID: 25381063 DOI: 10.1007/s00432-014-1864-3] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
43 Zhang Y, Wang S, Yang B, Lu S, Du Y, Liu H. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients. Cancer Biol Med 2019;16:350-60. [PMID: 31516755 DOI: 10.20892/j.issn.2095-3941.2018.0378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, Li J. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther 2021;29:1794-807. [PMID: 33484968 DOI: 10.1016/j.ymthe.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
45 Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? Crit Rev Oncol Hematol. 2021;157:103167. [PMID: 33271389 DOI: 10.1016/j.critrevonc.2020.103167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
46 Meng Y, Yu Z, Wu Y, Du T, Chen S, Meng F, Su N, Ma Y, Li X, Sun S, Zhang G. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application. Hum Vaccin Immunother 2017;13:1-9. [PMID: 28301281 DOI: 10.1080/21645515.2017.1285987] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
47 Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Cancers (Basel) 2019;11:E1078. [PMID: 31366113 DOI: 10.3390/cancers11081078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
48 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
49 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Reference Citation Analysis]
50 Guo Q, Li J, Lin H. Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. Biomed Res Int 2015;2015:261620. [PMID: 26161392 DOI: 10.1155/2015/261620] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
51 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Reference Citation Analysis]
52 Wang J, Feng L, Zhang L. Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101440. [PMID: 32709504 DOI: 10.1016/j.clinre.2020.04.010] [Reference Citation Analysis]
53 Gao D, Cai Y, Chen Y, Li W, Wei CC, Luo X, Wang Y. Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity. Oncol Lett 2018;15:5105-10. [PMID: 29552145 DOI: 10.3892/ol.2018.7954] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Yuan BH, Li RH, Yuan WP, Yang T, Tong TJ, Peng NF, Li LQ, Zhong JH. Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. Oncotarget. 2017;8:18537-18549. [PMID: 28061472 DOI: 10.18632/oncotarget.14507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
55 Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019; 25(25): 3151-3167 [PMID: 31333308 DOI: 10.3748/wjg.v25.i25.3151] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
56 Wang H, Liu A, Bo W, Feng X, Hu Y, Tian L, Zhang H, Tang X. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis. Digestive and Liver Disease 2016;48:1275-82. [DOI: 10.1016/j.dld.2016.07.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]